ICG-99mTc-nanoscan
Oral Cancer
The Netherlands Cancer InstituteN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Oral Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Loren Mell, MD | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Pembrolizumab Loren Mell, MD | Phase 2 | CCC |
(18F)FPPRGD2 Sanjiv Sam Gambhir | Phase 1/2 | CCC |
FLUDEOXYGLUCOSE Sanjiv Sam Gambhir | Phase 1/2 | CCC |
View all 21 →
Same molecule, other indications
ICG-99mTc-nanoscan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →